Should I Buy EKSO? EKSO 2026 Analysis

Should You Buy Ekso Bionics Holdings Inc (EKSO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

10.410

1 Day change

11.22%

52 Week Range

12.700

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the stock is extended after a +6.39% move and is already above R1 (9.46) and near R2 (9.98) while momentum (MACD histogram) is still weakening.
Intellectia signals do not support an urgent entry: no AI Stock Picker or SwingMax buy signals today.
Options tape is effectively inactive (zero OI/volume in the provided snapshot), offering no confirming bullish sentiment.
Fundamentals show only modest revenue growth (Q3 2025) while losses and EPS deteriorated YoY; this weakens the case for chasing strength.
With no near-term news catalyst and pattern-based probabilities skewing negative over 1W/1M, I would avoid buying here; if already holding, selling/trim into this strength is favored.

Technical Analysis

Trend/moving averages: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating an uptrend bias.
Momentum: MACD histogram at -0.0513 (below zero) and negatively expanding, signaling fading upside momentum despite the bullish MA stack.
RSI: RSI_6 at 53.50 (neutral) — no strong overbought/oversold edge.
Levels: Pivot 8.62; support S1 7.78 (then S2 7.26). Resistance R1 9.46 has been reclaimed; next resistance R2 9.979 is close overhead (limited immediate upside room).
Quant/pattern read-through: Similar-pattern projection shows ~50% chance of -2.37% next day, -8.35% next week, and -17.89% next month.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Reported open interest and volume are 0 (calls and puts), so the options market snapshot does not provide a meaningful sentiment read.
Volatility is extreme in the dataset: 30D IV 496.61 vs historical volatility 103.79 (very high optionality/pricing), but without volume/OI it’s not a strong actionable signal.
IV percentile/rank are moderate (IV percentile 26.87, IV rank 22.86), suggesting IV is not at the highest relative extremes, despite being high in absolute terms.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical uptrend structure remains intact (SMA alignment bullish).
- Gross margin improved to 60.3% in 2025/Q3 (+12.71% YoY), a constructive operating signal.
- Strategic review (per analyst note) can act as an event-driven catalyst if it leads to a value-unlocking transaction.
- Upcoming earnings: QDEC 2025 earnings on 2026-03-03 (after hours) can re-rate the stock if results/forward commentary improve.

Neutral/Negative Catalysts

- Bearish momentum divergence: MACD histogram below zero and deteriorating while price is strong.
- Price is pressing into resistance (near R2 9.979), which often caps short-term upside for impatient entries.
- Financial deterioration YoY in Q3 2025: net loss widened and EPS fell materially.
- No news in the last week (no fresh catalyst to justify chasing).
- Options market inactivity in the snapshot (no confirming bullish positioning).
- No notable hedge fund or insider accumulation signals recently (both neutral).
- Congress trading: no recent congress trading data available (no supportive “influential buyer” signal).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 4.227M, up +2.37% YoY (modest growth).
Profitability: Net income -1.421M, down -31.42% YoY (loss widened).
EPS: -0.54, down -64.71% YoY (meaningfully worse).
Gross margin: 60.3%, up +12.71% YoY (operational bright spot, but not yet translating into earnings improvement).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest cited update (2025-11-18): H.C. Wainwright reiterated Buy and raised price target to $6 from $4, citing a solid Q3 and a strategic review.
Trend summary: Rating stayed positive (Buy maintained) and the price target moved up (bullish revision).
Wall Street pros view: sales recovery narrative + strategic review optionality + improving gross margin.
Wall Street cons view: profitability is still worsening (net loss/EPS down YoY), and the current price (9.69) is above the cited $6 target, implying limited support from that target for buying at today’s level.

Analyst Rating

Wall Street analysts forecast EKSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 9.360

Low

Averages

High

Current: 9.360

Low

Averages

High

H.C. Wainwright

Buy

maintain

$4 -> $6

AI Analysis

2025-11-18

Reason

H.C. Wainwright

Price Target

$4 -> $6

AI Analysis

2025-11-18

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Ekso Bionics to $6 from $4 and keeps a Buy rating on the shares. The company reported a solid Q3 report and announced it has initiated a strategic review of the current business, the analyst tells investors in a research note. The firm does not account for any transaction at this time. Ekso's sales recovery in Q3 implies that order delays from the prior quarter "appear to be idiosyncratic," but it remains to be seen if this trend can continue, contends H.C. Wainwright.

Lake Street

Buy

downgrade

$15

2025-07-29

Reason

Lake Street

Price Target

$15

2025-07-29

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Ekso Bionics to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell "well below" the firm's expectations, attributable to the company's Enterprise Health business. While the firm does not believe investors "should become overly concerned with the company's Q2 results," it recognizes improvements "may not be readily evident prior to the company requiring additional funds."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EKSO

Unlock Now

EKSO Should I Buy

EKSO Should I Buy

Should You Buy Ekso Bionics Holdings Inc (EKSO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch